Predictive Oncology says court denies Renovaro motion for expedited trial

Predictive Oncology (POAI) issued the following statement regarding its dispute with Renovaro (RENB): “Contrary to a press release issued by RENB, the Delaware Court of Chancery recently rejected RENB’s request for an expedited, two-day trial in July. The Court reached this decision citing RENB’s delay in bringing its action. POAI fully intends to protect its rights and defend against the claims asserted by RENB that are premised on inaccurate allegations and lack any merit. The Court has scheduled trial for November 12-13, 2025. POAI looks forward to its day in Court.”